Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. For our second video in this month of gratitude, David Ringen stepped in front of the camera.
Don't forget to check out our social media – GRACE's Twitter, Facebook, YouTube, and Instagram feeds – and be sure to follow us on at least one of those platforms, where we hope you'll also share your own photos or thoughts on gratitude.
Keep checking in to see the newest information about lung cancer treatments. We encourage you to share GRACE with the lung cancer patients and caregivers in your life so that they can benefit as well.
We would like to thank Keith Singer at Catch It in Time, who produced the videos, to Gilles Frydman and Laya Dogmetchi who took the portraits you will see throughout the month, to the patients and caregivers who stepped in front of our cameras with open and grateful hearts, and to you, the people who visit the GRACE website and read our materials on a regular basis. Thank you for appreciating our work.
And thanks to the following companies for their support of our LCAM 2016 program
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…